Abstract : Recently, organ-preserving regimens using predominantly multiple-modality therapy , consisting of endoscopic transurethral resection followed by irradiation with concurrent chemotherapy, are emerging as viable alternatives for muscle-invasive bladder cancer, although radical cystectomy has been the standard treatment. Three cases with muscle-invasive bladder cancer (5-7 cm in size) , two of T2N1M0 and one of T2NOMO, underwent bladder preservation therapy with regional hyperthermia for improvement of the local effect. A total dose of 66-7OGy in the conventional methods , chemotherapy composed of methotrexate, doxorubicin, cisplatin and/or vinblastine, and 3 to 12 sessions of hyperthermia during radiotherapy were delivered. All three cases showed complete response without any local recurrence or distant metastasis in follow-ups. Toxicity during the treatment was acceptable, and late toxicity was not recognized. Bladder preservation therapy adding regional hyperthermia is potentially useful for improving the treatment results for muscle-invasive bladder cancer of large tumor size.
Introduction
Muscle-invasive tumors comprise 20 % to 25 % of all newly diagnosed bladder cancerso. The most appropriate treatment algorithm for muscle-invasive bladder cancer remains controversial. Although radical cystectomy has been the standard treatment for two decades, organ-preserving regimens using predominantly multiple-modality therapy, consisting of endoscopic transurethral resection (TUR) followed by irradiation with concurrent chemotherapy, are emerging as viable alternatives in a subset of patients.
A major limitation of pelvic external beam radiation therapy is that the dose required to achieve an adequate level of local control in such tumors exceeds the tolerance of the surrounding normal tissues .
Hyperthermia has been used in combination with radiation therapy and/or chemotherapy, and considered to be effective for certain type of tumors2-6). Treatment results of radiotherapy and/or chemotherapy plus hyperthermia for bladder cancer were also reported7-12). Improvement of the local effect by hyperthermia is especially expected in large tumors. In the present three cases, bladder preservation therapy, consisting of TUR followed by irradiation with concurrent chemotherapy and regional hyperthermia, was used to treat with muscle-invasive bladder cancer of large tumor size.
Materials and methods

Patients
Between January 2000 and December 2002, three patients with invasive bladder cancer were treated with chemoradiotherapy plus regional hyperthermia at our hospital. Characteristics and treatments of patients are given in Table I . TUR was used for both diagnosis and treatment as reducing the tumor volume in all the three patients. Acute toxicity was scored according to criteria of radiation therapy oncology group13). Late toxicity was mainly investigated by a telephone to the patients or their family.
Hyperthermia
Hyperthermia was applied with radiofrequency (RF)-capacitive heating device (Thermotron RF-8)
within 30 min after radiotherapy once or twice a week. Heating duration was 40-50 min. Both upper and lower electrodes were 30 cm in diameter, placed on opposite sides of urinary bladder. The out-put power was about 400-600W. A treatment posture of all cases was prone position. For cooling of the skin surface, the overlay boluses were applied in addition to regular boluses attached in front of the metal electrodes. The intravesical temperature was measured using a 4-point microthermocouple-sensor. The maximum intravesical temperature (Tmax) was defined as the maximum intravesical temperature obtained during the steady state and at the end of treatment. The steady state was defined at 20 min after the start of heating. The minimum intravesical temperature (Tmin) was defined as the minimum temperature obtained by the same method. The averages of these parameters (Tave) were calculated over the steady state. In all cases, Tmax, Tmin and Tave were measured at the third session. 
Evaluation of tumor response
The clinical tumor response was evaluated by measuring the tumor size with MR imaging before and after the radiation therapy. Grading of tumor response was as follows : complete response (CR), 50 % regression in volume as partial response (PR), < 50 % response or < 25 % increase as no change (NC).
Results
Table II summarizes the treatment result. CR was achieved in all the three patients. They did not have both local recurrence and distant metastasis. Fig. 1 . shows MRI images of case 1 with bulky bladder cancer which responded completely to combined treatments. Toxicity consisted of cystitis and diarrhea noted during the treatment was acceptable and did not get serious. Acute toxicity of chemotherapy was also within the tolerance level. Severe late toxicity was not recognized in our retrospective research. 
Discussion
Radical radiation therapy as the sole treatment modality for muscle-invasive bladder cancer has produced a clinical complete response in 40 % to 50 % of patients14-16). Several authors have reported promising results of concurrent chemoradiotherapy for muscle-invasive bladder cancer17-22). Pelvic failure is less common with chemoradiotherapy than with radiation monotherapy22). For the modern bladder preservation series, TUR followed by irradiation with concurrent chemotherapy, the overall survival at 5 years ranged from 45 to 52 % ; 54 to 67 % of surviving patients have a tumor-free, normally functioning bladder1).
Hyperthermia is biologically known as an effective modality for treatment of cancer. Clinical studies including randomized trials on hyperthermia have promising results for various sites of tumor2-12). A Dutch phase III trial showed improvement of local efficacy in a mixed cohort of patients with locally advanced cervical, bladder or rectal carcinoma, and a major survival benefit was obtained in patients with cancer of the uterine cervix by adding regional hyperthermia to standard radiation therapy12). For patients with bladder cancer, the addition of hyperthermia significantly increased the complete-response rate from 51 % to 73 % ; however, long-term local control and overall survival were not significantly improved. The value of hyperthermia in these patients might have been underestimated for various reasons as lack of thermal data analysis and the problem of patients who received insufficient hyperthermia treatment.
Clinical and laboratory studies have also shown that hyperthermia enhance the cytotoxic effects of several chemotherapeutic drug7)23)24). Kakehi et al. showed the treatment results of RF-capacitive regional hyperthermia with chemotherapy in patients with bladder cancer ; total response rate was obtained in 6 out of 8 cases7). Although there were a few reports of combined treatment of hyperthermia, irradiation and chemotherapy for invasive bladder carcinoma, their results were satisfactory8-10). In the combination therapy consisted of radiation and hyperthermia administered by way of warmed saline and 
